Ayrignac Xavier, Bigaut Kevin, Pelletier Jean, de Seze Jérôme, Demortiere Sarah, Collongues Nicolas, Maarouf Adil, Pinna Frédéric, Aouinti Safa, Carra Dallière Clarisse, Kremer Laurent, Charif Mahmoud, Picot Marie Christine, Labauge Pierre
CRC SEP, Montpellier University Hospital, INSERM, Univ Montpellier, Montpellier.
CRC-SEP, Neurologie, Hôpital de Hautepierre, Strasbourg, France.
Mult Scler Relat Disord. 2021 Feb;48:102686. doi: 10.1016/j.msard.2020.102686. Epub 2020 Dec 13.
The advent of new, potent, disease-modifying therapies has dramatically changed the management of multiple sclerosis (MS). Along with these possibilities, it is crucial to better recognize patients who are at risk of first line treatment (FLT) failure and switch to highly effective therapies (HET).
To identify baseline prognostic factors associated with FLT failure in relapsing remitting MS (RR-MS) patients.
We included recently diagnosed RR-MS patients starting an FLT identified from 3 French MS centers databases. Baseline characteristics were included in a multivariable Cox analysis to identify the main factors associated with FLT failure.
Eight hundred sixty-three patients were included. We observed an overall rate of treatment failure of 23.5%. The main baseline characteristics associated with treatment failure were age <26 years at treatment start (HR= 2.1, p<0.001), EDSS ≥2 (HR=2.1, p<0.001) and ≥2relapses in the previous year (HR=1.5, p=0.04). The association with the presence of gadolinium enhancement on MRI was not statistically significant. EDSS progression was only significantly associated with age at treatment start and treatment failure.
Our series demonstrates that some clinical and imaging factors are associated with treatment failure, and should be considered when planning treatment strategy in patients with recently diagnosed RR-MS.
新型强效疾病修正疗法的出现极大地改变了多发性硬化症(MS)的治疗方式。伴随着这些可能性,更好地识别有一线治疗(FLT)失败风险并转而使用高效疗法(HET)的患者至关重要。
确定复发缓解型多发性硬化症(RR-MS)患者中与FLT失败相关的基线预后因素。
我们纳入了从3个法国MS中心数据库中识别出的开始接受FLT治疗的新诊断RR-MS患者。基线特征纳入多变量Cox分析,以确定与FLT失败相关的主要因素。
共纳入863例患者。我们观察到总体治疗失败率为23.5%。与治疗失败相关的主要基线特征为治疗开始时年龄<26岁(HR = 2.1,p<0.001)、扩展残疾状态量表(EDSS)≥2(HR = 2.1,p<0.001)以及前一年复发≥2次(HR = 1.5,p = 0.04)。MRI上钆增强的存在与之的关联无统计学意义。EDSS进展仅与治疗开始时的年龄及治疗失败显著相关。
我们的系列研究表明,一些临床和影像学因素与治疗失败相关,在为新诊断的RR-MS患者制定治疗策略时应予以考虑。